Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Videos

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

News

AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC

News

AACR 2021: Influence of Aneuploidy on Response to Immunotherapy for Lung Cancer

News

Priority Review Granted by FDA for Mobocertinib in Subtype of NSCLC

News

Updated USPSTF Recommendation on Lung Cancer Screening

Medical Literature

Lung Cancer Screening Amid the COVID-19 Pandemic

Medical Literature

NSCLC With Brain Metastases: Concurrent Chemotherapy and Whole-Brain Radiotherapy

Masahiro Tsuboi, MD, on Osimertinib as Adjuvant Treatment in EGFR-Mutated NSCLC

Silvia Novello, MD, PhD, on NSCLC Treatment Guided by Pharmacogenomics

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

View More

More

News

Priority Review Granted by FDA for Mobocertinib in Subtype of NSCLC

WCLC 2020: Novel Tyrosine Kinase Inhibitor Versus Chemotherapy for EGFR-Mutated NSCLC

FDA Approves Cemiplimab-rwlc and Expands Approval of Companion Diagnostic in NSCLC

Novel Bispecific PD-L1 and CTLA-4 Antibody for Metastatic NSCLC

WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC

WCLC 2020: KEYNOTE-799 Update on Pembrolizumab With Chemoradiotherapy in Stage III Lung Cancer

Brigatinib in Alectinib-Resistant ALK-Positive NSCLC

Tyrosine Kinase Inhibitor Combination Therapy for HER2-Mutated NSCLC

View More

Advertisement

Published

Medical Literature

Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer

Multikinase Inhibitors in RET-Rearranged NSCLC

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

Brigatinib in Patients With Crizotinib-Refractory ALK-Positive NSCLC

View More

Ongoing

CE Activities

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Novel and Emerging Therapeutic Strategies in the Management of Non–Small Cell Lung Cancer

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Consensus or Controversy? Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.